外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

doi:10.16352/j.issn.1001-6325.2023.09.1457

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (9): 1457-1461.doi: 10.16352/j.issn.1001-6325.2023.09.1457

外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

颜晨红¹, 金儿^2*

1.浙江中医药大学第四临床医学院,浙江杭州 310000;
2.浙江大学医学院附属杭州市第一人民医院呼吸内科, 浙江杭州 310000

收稿日期:2022-08-25 修回日期:2022-12-04 出版日期:2023-09-05 发布日期:2023-09-01
通讯作者: ^*amyier@163.com
基金资助:
杭州市科技计划引导项目(20201231Y023);浙江省基础公益研究计划(LY19H160031);浙江省医药卫生科技计划(2019KY126)

Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer

YAN Chenhong¹, JIN Er^2*

1. The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000;
2. Department of Respiratory Medicine,Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

Received:2022-08-25 Revised:2022-12-04 Online:2023-09-05 Published:2023-09-01
Contact: ^*amyier@163.com

摘要/Abstract

摘要： 外泌体PD-L1(exoPD-L1)可由非小细胞肺癌中癌细胞分泌,参与肿瘤的发生发展。外泌体PD-L1的检测具有无创、稳定等优点,可早期诊断非小细胞肺癌、判断肿瘤分期。外泌体PD-L1与肿瘤组织PD-L1相关,可用于筛选免疫治疗优势人群。动态监测外泌体PD-L1表达水平可评估肺癌患者免疫治疗效果。抑制外泌体PD-L1可辅助免疫治疗,为肺癌晚期患者的免疫治疗提供了较佳的临床价值。

关键词: 非小细胞肺癌, 外泌体, PD-L1, 诊断, 免疫治疗

Abstract: Exosomal PD-L1(exoPD-L1) is secreted by cancer cells in some patients with non-small cell lung cancer and this molecule participates in the development of tumors. As liquid biopsy detection, the detection of exosomal PD-L1 has a great deal of advantages, such as non-invasive and stable. Furthermore, exosomal PD-L1 has a bright prospect in early diagnosis in lung cancer, which also has close contact with TNM of non-small cell lung cancer. Exosomal PD-L1 is related to tumor tissue PD-L1 and can be used to select people who in deed suit immumunotherapy.Monitoring exosomal PD-L1 dynamically is meaningful for evaluating the effects of immunotherapy in patients with non-small cell lung cancer. Study has found that blocking the secretion of exosomal PD-L1 could assist immunotherapy. The application of exosomal PD-L1 is quite potential to the treatment of patients at advanced stage of non-small cell lung cancer.

Key words: non-small cell lung cancer, exosome, PD-L1, diagnosis, immunotherapy

中图分类号:

R734.2

颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.

YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer[J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.

参考文献 28

[1]	Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52: 103-109.
[2]	Ma Y, Marinkova R, Nenkov M, et al. Tumor-intrinsic PD-L1 exerts an oncogenic function through the activation of the Wnt/β-catenin pathway in human non-small cell lung cancer[J]. Int J Mol Sci, 2022, 23:11031. doi: 10.3390/ijms231911031.
[3]	Zhang J, Zhu Y, Guan M, et al. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response[J]. Nanoscale, 2022, 14:8995-9003.
[4]	Yoh KE, Lowe CJ, Mahajan S, et al. Enrichment of circulating tumor-derived extracellular vesicles from human plasma[J]. J Immunol Methods, 2021;490:1129363. doi:10.1016/j.jim.2020.112936.
[5]	杨旭东,于红亮,李静,等.巨噬细胞J774A.1外泌体促进结直肠癌细胞系MC38和CT26的增殖和迁移[J]. 基础医学与临床, 2021, 41:799-804.
[6]	彭晓潇,刘思思,宋丹妮,等.非小细胞肺癌血浆外泌体PD-L1检测的可行性研究[J]. 循证医学, 2019, 19:119-123.
[7]	Zhang W, Zhong W, Wang B, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression[J].Dev Cell, 2022, 57:329-343.
[8]	Ji C, Yang S, Feng M, et al. PD-L1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis[J]. Cancer Sci, 2021,112: 3437-3454.
[9]	Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med, 2019,51: 1-13.
[10]	Wu Y, Zeng X, Gan Q. A compact surface plasmon resonance biosensor for sensitive detection of exosomal proteins for cancer diagnosis[J].Methods Mol Biol, 2022, 2393:3-14.
[11]	Yang Y, Kannisto E, Yu G, et al. An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNAs for cancer diagnosis[J]. ACS Appl Mater Interfaces, 2018, 10:43375-43386.
[12]	Sha L, Bo B, Yang F, et al. Programmable DNA-fueled electrochemical analysis of lung cancer exosomes[J]. Anal Chem, 2022, 94:8748-8755.
[13]	Li C, Li C, Zhi C, et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients[J]. J Transl Med, 2019, 17:355. doi: 10.1186/s12967-019-2101-2.
[14]	Zhang Z, Jin W, Xu K, et al. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer[J], Tissue Cell, 2022, 79:101941. doi:10.1016/j.tice.2022.101941.
[15]	Shimada Y, Matsubayashi J, Kudo Y, et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer[J]. Sci Rep, 2021, 11: 7830. doi:10.1038/s41598-021-87575-3.
[16]	Yu S, Shi M, Feng J. Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues[J]. Ann Oncol, 2019, 30:v43. doi:10.1093/annonc/mdz239.
[17]	Wu F, Gu Y, Kang B, et al. PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer[J]. Transl Lung Cancer Res, 2021, 10:2441-2451.
[18]	Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7:e1438111. doi:10.1080/2162402X.2018.1438111.
[19]	Wang Y, Niu X, Cheng Y, et al. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients[J].Clin Exp Immunol, 2022, 208:316-322.
[20]	Zhang C, Fan Y, Che X, et al. Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28[J].Front Oncol, 2020, 10:760. doi:10.3389/fonc.2020.00760.
[21]	De Miguel-Perez D, Russo A, Arrieta O, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer[J].J Exp Clin Cancer Res, 2022, 41:186. doi:10.1186/s13046-022-02379-1.
[22]	Del Re M, Marconcini R, Pasquini G, et al. PD-L1 mRNA expression in plasma-derived exosomes is associ-ated with response to anti-PD-1 antibodies in melanoma and NSCLC[J]. Br J Cancer, 2018, 118: 820-824.
[23]	Cordonnier M, Nardin C, Chanteloup G, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients[J]. J Extracell Vesicles, 2020, 9:1710899. doi:10.1080/20013078.2019.1710899.
[24]	Yang Q, Chen M, Gu J, et al. Novel biomarkers of bynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients[J]. Front Immunol, 2021, 12:665133.doi:10.3389/fimmu.2021.665133.
[25]	Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)[J]. J Exp Clin Cancer Res, 2020, 39:149. doi:10.1186/s13046-020-01648-1.
[26]	Lee CH, Bae JH, Choe EJ, et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1[J]. Theranostics, 2022, 12:1971-1987.
[27]	Yin Z, Yu M, Ma T, et al. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1[J]. J Immunother Cancer, 2021, 9:e001698. doi:10.1136/jitc-2020-001698.
[28]	Xie L, Li J, Wang G, et al. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy[J].J Am Chem Soc, 2022, 144:787-797.

外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[3]	赵俊丽, 朱君君, 詹秋楠, 刘苗. 骨髓间充质干细胞来源外泌体抑制高糖诱导的腹膜间皮细胞EMT[J]. 基础医学与临床, 2024, 44(8): 1149-1156.
[4]	郑红, 陈晓霞, 韩李周, 陈苗, 皇甫娟. 降低lncRNA-RMRP表达抑制人肺癌细胞系A549的增殖和侵袭[J]. 基础医学与临床, 2024, 44(7): 974-978.
[5]	胡潮兴, 梁秋冬, 吴大鹏. 血清SAA4和SOCS1对脊柱结核与化脓性脊柱炎的早期鉴别价值[J]. 基础医学与临床, 2024, 44(7): 997-1001.
[6]	张睿, 谭妍, 马东来, 王蓉蓉, 张学. KIT杂合大片段缺失导致斑驳病一家系的临床表型[J]. 基础医学与临床, 2024, 44(7): 954-958.
[7]	高璐, 蔡孟华, 许依, 何维, 陈慧, 张建民. 过表达膜定位IL-3的293T细胞外泌体的纯化及体外功能验证[J]. 基础医学与临床, 2024, 44(7): 947-953.
[8]	梁香存, 魏小雨, 梁健, 王庆, 耿广. 安罗替尼通过调控miR-16-5p/PD-1轴抑制人非小细胞肺癌细胞系增殖并促进凋亡[J]. 基础医学与临床, 2024, 44(4): 503-512.
[9]	王宇, 童安莉, 周玥, 张文倩, 崔云英, 景红丽, 李玉秀. ^99mTc-HYNIC-TOC显像和¹³¹I-MIBG显像在嗜铬细胞瘤和副神经节瘤中的诊断价值[J]. 基础医学与临床, 2024, 44(3): 374-378.
[10]	张婧, 杨自更, 蔡文琴, 曹维维, 韦红梅, 薛茜茜, 吴宾. 抑制抗增殖蛋白2增强非小细胞肺癌细胞系A549对厄洛替尼敏感性[J]. 基础医学与临床, 2024, 44(3): 325-332.
[11]	赵永忠, 薛懿, 李立群, 侯孟森, 杨晓军. 胆囊癌的早期影像学及循环标志物特征[J]. 基础医学与临床, 2024, 44(2): 265-269.
[12]	李娟, 李晓峰, 徐生志, 唐凯. 华蟾素胶囊联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效[J]. 基础医学与临床, 2024, 44(2): 247-251.
[13]	丁飞, 王洒, 黄常新. 非小细胞肺癌患者血清CA211水平和NK细胞数与预后相关[J]. 基础医学与临床, 2024, 44(2): 180-184.
[14]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[15]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.